Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CASP6 | P55212 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | GLA | P06280 | 3/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14428357 | 0.81 | CA12 (0.57) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL6426203 | 0.81 | CA12 (0.40) | CA12CA1CA2CA9POLB | |
| SCHEMBL15009297 | 0.80 | CA12 (0.52) | CA12CA1CA2CA9POLB | |
| SCHEMBL5452602 | 0.80 | CA12 (0.53) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL11785663 | 0.80 | CA12 (0.44) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL5451586 | 0.79 | CA12 (0.55) | CA12CA1CA2CA9 | |
| Diethylamine SCHEMBL6365058 | 0.79 | CA12 (0.52) | CA12CA1CA2CA9 | |
| SCHEMBL14428354 | 0.79 | CA12 (0.52) | CA12CA1CA2CA9MAPK1 | |
| SCHEMBL14428416 | 0.79 | CA12 (0.55) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL5469423 | 0.79 | CA12 (0.52) | CA12CA1CA2CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | LEE WILLIAM W (US) | 2005-07-14 | — | — | US | disclosed |
| US-6828321-B2 | Compounds specifically radiosensitize hypoxic tumor cells | SRI INTERNATIONAL | 2004-12-07 | — | — | US | disclosed |
| US-20020103200-A1 | 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents | LEE WILLIAM W (US) | 2002-08-01 | — | — | US | disclosed |
| US-6362184-B1 | KILLING TUMOR CELLS | SRI INTERNATIONAL | 2002-03-26 | — | — | US | disclosed |
| US-5849738-A | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | SRI INTERNATIONAL (US) | 1998-12-15 | — | — | US | disclosed |
| US-5624925-A | RADIOACTIVE MATERIALS FOR TUMOR DETECTION | SRI INTERNATIONAL (US) | 1997-04-29 | — | — | US | disclosed |
| US-5616584-A | ADMINISTERING A SENSITIZER PRIOR ANTITUMOR RADIATION THERAPY | SRI INTERNATIONAL (US) | 1997-04-01 | — | — | US | disclosed |
| US-5175287-A | Lower alkyl nitrite under reductive deamination | S R I INTERNATIONAL (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0478545-A4 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | STANFORD RES INST INT (US) | 1992-08-05 | — | — | EP | disclosed |
| EP-0413706-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1991-02-27 | — | — | EP | disclosed |
| WO-1989008647-A1 | 1,2,4-BENZOTRIAZINE OXIDES AS RADIOSENSITIZERS AND SELECTIVE CYTOTOXIC AGENTS | SRI INTERNATIONAL (US) | 1989-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103200-A1 | 1,2,4-Benzotriazine oxides as radiosensitizers and selective cytotoxic agents | HYOU1, HIF1AN, HIF1A | CA12 2201/4885CA1 342/4885CA2 33/4885 |
| US-20050153961-A1 | 1, 2, 4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents | HYOU1, HIF1AN, HIF1A | CA12 2201/4885CA1 342/4885CA2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.